1. Home
  2. ARQT vs ECC Comparison

ARQT vs ECC Comparison

Compare ARQT & ECC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ARQT
  • ECC
  • Stock Information
  • Founded
  • ARQT 2016
  • ECC N/A
  • Country
  • ARQT United States
  • ECC United States
  • Employees
  • ARQT N/A
  • ECC N/A
  • Industry
  • ARQT Biotechnology: Pharmaceutical Preparations
  • ECC
  • Sector
  • ARQT Health Care
  • ECC
  • Exchange
  • ARQT Nasdaq
  • ECC NYSE
  • Market Cap
  • ARQT 1.1B
  • ECC 940.6M
  • IPO Year
  • ARQT 2020
  • ECC N/A
  • Fundamental
  • Price
  • ARQT $10.05
  • ECC $8.98
  • Analyst Decision
  • ARQT Strong Buy
  • ECC Buy
  • Analyst Count
  • ARQT 5
  • ECC 2
  • Target Price
  • ARQT $14.40
  • ECC $11.00
  • AVG Volume (30 Days)
  • ARQT 2.3M
  • ECC 679.0K
  • Earning Date
  • ARQT 11-06-2024
  • ECC 02-22-2024
  • Dividend Yield
  • ARQT N/A
  • ECC 19.16%
  • EPS Growth
  • ARQT N/A
  • ECC 369.44
  • EPS
  • ARQT N/A
  • ECC 1.69
  • Revenue
  • ARQT $138,708,000.00
  • ECC $122,654,279.00
  • Revenue This Year
  • ARQT $208.32
  • ECC $36.58
  • Revenue Next Year
  • ARQT $48.56
  • ECC $12.88
  • P/E Ratio
  • ARQT N/A
  • ECC $5.93
  • Revenue Growth
  • ARQT 182.84
  • ECC 96.41
  • 52 Week Low
  • ARQT $1.76
  • ECC $8.60
  • 52 Week High
  • ARQT $13.17
  • ECC $11.79
  • Technical
  • Relative Strength Index (RSI)
  • ARQT 57.11
  • ECC 25.07
  • Support Level
  • ARQT $8.90
  • ECC $8.90
  • Resistance Level
  • ARQT $10.42
  • ECC $9.80
  • Average True Range (ATR)
  • ARQT 0.68
  • ECC 0.17
  • MACD
  • ARQT 0.06
  • ECC -0.06
  • Stochastic Oscillator
  • ARQT 61.90
  • ECC 4.41

About ARQT Arcutis Biotherapeutics Inc.

Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's lead product candidate ZORYVE roflumilast cream, has successfully completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.

About ECC EAGLE POINT CREDIT CO LLC

Eagle Point Credit Co Inc is an externally managed, non-diversified closed-end management investment company.

Share on Social Networks: